Business Context and Reporting Period
This Form 8-K Current Report was filed by AmerisourceBergen Corporation (now Cencora, Inc.) on November 12, 2009. The filing reports on corporate governance actions, capital allocation decisions, and legal contingencies occurring on that date.
Key Financial Metrics and Capital Actions
- Dividend Increase: The quarterly dividend rate was increased by 33 percent, from $0.06 to $0.08 per common share. A dividend of $0.08 per share was declared, payable on December 7, 2009, to stockholders of record as of November 23, 2009.
- Share Repurchase Program: The Board of Directors authorized a new share repurchase program with a total authorization of $500 million, effective immediately.
- Financial Performance: The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity for the reporting period.
Material Changes and Corporate Actions
- Expiration of Rights Agreement: The company amended its Amended and Restated Rights Agreement to accelerate the expiration of outstanding rights. The rights will expire at the close of business on November 20, 2009, rather than the original date of August 27, 2011.
- Elimination of Preferred Stock: Upon the expiration of the rights, the company will file a Certificate of Elimination with the Delaware Secretary of State to eliminate the Certificate of Designations for its Series A Preferred Stock.
Risks, Contingencies, and Management Commentary
The filing highlights a significant legal contingency involving qui tam (whistleblower) litigation under the federal and state False Claims Acts.
- Pending Litigation: A qui tam matter is pending in the U.S. District Court for the District of Massachusetts. The case names AmerisourceBergen Corporation and two of its business units (ASD Specialty Healthcare, Inc. and International Nephrology Network) as defendants alongside Amgen Inc.
- Allegations: The complaints allege that from 2002 through 2009, the defendants conspired with Amgen to promote the anemia drug Aranesp in violation of health laws, causing medical providers to submit false certifications and claims to federal and state health programs (including Medicare and Medicaid).
- Government Investigation: The Department of Justice (DOJ) issued a subpoena for records on June 22, 2009. The company is cooperating with the DOJ inquiry. The filing notes that additional sealed qui tam suits may exist due to the ongoing investigation.
- Impact: The company states that its business and results of operations could be adversely affected if found liable or if government authorities intervene in the pending or potential cases.
Investor Verification Checklist
- Verify the exact timing and mechanics of the rights expiration on November 20, 2009.
- Confirm the status of the $500 million share repurchase program and any subsequent buyback activity.
- Monitor the status of the qui tam litigation involving Aranesp and the DOJ investigation for updates on potential financial liabilities.
- Review the company's most recent Form 10-K for baseline financial metrics not included in this 8-K.